Skip to product information
1 of 1

OX40/TNFRSF4/CD134 Fc Chimera Protein, Cynomolgus

OX40/TNFRSF4/CD134 Fc Chimera Protein, Cynomolgus

Catalog Number: UA010869 Reactivity: Cynomolgus Conjugation: Unconjugated Brand: UA BIOSCIENCE
Price:
Regular price $268 USD
Regular price Sale price $268 USD
Size:
For shipping services or bulk orders, you may request a quotation.
Secure checkout with
View full details

Product Details

Product Specification


Species Cynomolgus
Synonyms Txgp1; OX40L receptor; ACT35
Accession XP_001090870.1
Amino Acid Sequence Lys28-Ala214, with C-terminal hIgG1 Fc
Expression System HEK293
Molecular Weight 65-72kDa (Reducing)
Purity >95% by SDS-PAGE
Endotoxin <0.1EU/μg
Conjugation Unconjugated
Physical Appearance Lyophilized Powder
Storage Buffer PBS, pH7.4.
Reconstitution Reconstitute at 0.1-1 mg/ml according to the size in ultrapure water after rapid centrifugation.
Stability & Storage · 12 months from date of receipt, lyophilized powder stored at -20 to -80℃.
· 3 months, -20 to -80℃ under sterile conditions after reconstitution.
· 1 week, 2 to 8℃ under sterile conditions after reconstitution.
· Please avoid repeated freeze-thaw cycles.
Reference

Cancer Res. Roles of OX40 in the pathogenesis and the control of diseases.Int J Hematol . 2006 Jan;83(1):17-22.

Background

OX40 belongs to the tumor necrosis factor receptor superfamily, and its expression is restricted to activated T-cells. Ligation of OX40 during T-cell-dendritic cell interaction is crucial for clonal expansion of antigen-specific T-cells and generation of T-cell memory. Recent studies with animal models have indicated the critical involvement of OX40 in the pathogenesis of a variety of immunologic abnormalities of inflammatory, autoimmune, infectious, allergic, and allotransplantation-related diseases. Blockade of OX40-OX40L(The ligand of OX40) interaction has been shown to prevent, cure, or ameliorate these diseases. In contrast, activation of OX40 is known to break an existing state of tolerance in malignancies, leading to a reactivation of antitumor immunity. These findings clearly suggest that the OX40/OX40L system is one of the most promising targets of immune intervention for treatment of these diseases.

Picture

Bioactivity

Immobilized OX40 Ligand/TNFSF4 His Tag, Cynomolgus (Cat. No. UA010778) at 2.0μg/mL (100μL/well) can bind OX40/TNFRSF4/CD134Fc Chimera, Cynomolgus (Cat. No. UA010869) with EC50 of 29.4-43.16ng/mL.

SDS-PAGE

1μg (R: reducing condition, N: non-reducing condition).

Customer Reviews

Be the first to write a review
0%
(0)
0%
(0)
0%
(0)
0%
(0)
0%
(0)